Effects of contraceptive use on bone biochemical markers in young women
- PMID: 11231998
- DOI: 10.1210/jcem.86.1.7118
Effects of contraceptive use on bone biochemical markers in young women
Abstract
The purpose of this study was to compare biochemical markers of bone resorption and formation in young women using different hormonal contraceptive methods. Women aged 18-39 yr who were using depot medroxyprogesterone acetate (DMPA) contraception were recruited for the study; comparison women were matched by age and clinic location. There were 116 women using DMPA, 39 using oral contraceptives containing estrogen and progestin, and 72 not currently using hormonal contraceptives. Biochemical measurements were serum calcium, PTH and osteocalcin, and urine N-telopeptide. Bone density was measured using dual-energy x-ray absorptiometry. The N-telopeptide levels, adjusted for age and other risk factors, were 42.4 +/- 2.3 nmol/mmol creatinine in the DMPA group, 26.2 +/- 3.3 nmol/mmol in the oral contraceptive group, and 35.4 +/- 2.9 nmol/mmol in the nonusers; significant differences were seen in all pairwise comparisons. Osteocalcin levels showed the same pattern, although the difference between the DMPA users and nonusers was not statistically significant. There were no differences among groups in the PTH levels. The bone density at the spine was 1.086 +/- 0.085 g/cm(2) in the DMPA group, 1.103 +/- 0.095 g/cm(2) in the oral contraceptive group, and 1.093 +/- 0.090 g/cm(2) in nonusers (P = 0.051). The results suggest that in women using DMPA bone resorption exceeded bone formation.
Similar articles
-
Differential effects on bone density of progestogen-only methods for contraception in premenopausal women.Contraception. 1995 Jul;52(1):35-9. doi: 10.1016/0010-7824(95)00121-p. Contraception. 1995. PMID: 8521712 Clinical Trial.
-
Bone density among long-term users of medroxyprogesterone acetate as a contraceptive.Contraception. 1998 Dec;58(6):351-5. doi: 10.1016/s0010-7824(98)00125-5. Contraception. 1998. PMID: 10095971 Clinical Trial.
-
Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling.Contraception. 2006 Oct;74(4):297-302. doi: 10.1016/j.contraception.2006.04.003. Epub 2006 Jun 16. Contraception. 2006. PMID: 16982229
-
Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.J Reprod Med. 1996 May;41(5 Suppl):401-6. J Reprod Med. 1996. PMID: 8725702 Review.
-
Depo Provera. Position paper on clinical use, effectiveness and side effects.Br J Fam Plann. 1999 Jul;25(2):69-76. Br J Fam Plann. 1999. PMID: 10454658 Review.
Cited by
-
Premenopausal women and low bone density.Can Fam Physician. 2006 Jun;52(6):743-7. Can Fam Physician. 2006. PMID: 16812966 Free PMC article. Review.
-
The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis.Hum Reprod Update. 2014 Jan-Feb;20(1):76-105. doi: 10.1093/humupd/dmt038. Epub 2013 Sep 29. Hum Reprod Update. 2014. PMID: 24082040 Free PMC article.
-
Bone health in estrogen-free contraception.Osteoporos Int. 2019 Dec;30(12):2391-2400. doi: 10.1007/s00198-019-05103-6. Epub 2019 Aug 24. Osteoporos Int. 2019. PMID: 31446440 Free PMC article. Review.
-
Premenopausal bone health assessment.Curr Rheumatol Rep. 2005 Mar;7(1):46-52. doi: 10.1007/s11926-005-0008-9. Curr Rheumatol Rep. 2005. PMID: 15760580 Review.
-
The association of pregnancy history with areal and volumetric bone mineral density in adolescence.Osteoporos Int. 2007 Jan;18(1):101-8. doi: 10.1007/s00198-006-0203-1. Epub 2006 Aug 26. Osteoporos Int. 2007. PMID: 16937071
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources